Fig 2: Pre- and post-training values (mean ± SD) for IL-6 in control (CG), Supplement (SG), training (TG), and Training + Supplement (TSG) groups. & Significant differences with pretest values (p < 0.05). * Significant differences with the control group (p < 0.05). # Significant interaction between time and groups (p < 0.05).

Fig 3: Correlation analysis of BMI with IL-1, IL-6, hs-CRP and aromatase activity. According to analysis results, the BMI had a positive association with IL-1 (A), IL-6 (B), and hs-CRP (C). No correlation was observed between the aromatase activity and BMI (D). Spearman’s correlation coefficient (r) was calculated to evaluate the variables relationship

Fig 4: Levels of IL-6 in patients with or without AKI. Appendix: 0—no AKI; 1—documented AKI.

Fig 5: Correlation of FGF21 levels with AT characteristics. (a) Spearman's rank correlations between circulating FGF21 levels and histological adipose tissue (AT) characteristics, alongside metabolic markers. Only tiles having significant correlations (p ≤ 0.05) are labelled with their corresponding effect size. Correlation direction is denoted by colour: positive correlations are red and negative ones are blue, with the depth of the hue reflecting the strength of the correlation. (b) Correlation assessments with circulating FGF21 were conducted for each transcript and protein derived from subcutaneous adipose tissue (scAT) or visceral adipose tissue (visAT). Candidates demonstrating significant positive correlations (p ≤ 0.05) are presented in red, while those showing negative correlations are illustrated in blue. The cumulative count of these significant candidates is provided. Pertinent candidates are clearly marked. For clarity, the top 25 and bottom 25 candidates in terms of correlation strength are rendered opaque. (c) Venn diagram showcasing the overlap between transcripts and proteins that significantly correlate with circulating FGF21 either positively or negatively (termed transcriptome/proteome negative or positive). Abbreviations: ALT (alanine aminotransferase), AST (aspartate aminotransferase), BMI (body mass index), BP (blood pressure), GGT (gamma glutamyl transferase), HDL (high-density lipoprotein), HOMA-IR (homeostatic model assessment of insulin resistance), CRP (c-reactive protein), IL6 (interleukin 6), LDL (low density lipoprotein), CDS2 (CDP-Diacylglycerol Synthase 2), CUL5 (Cullin-5), ITGB1 (Integrin Subunit Beta 1), DNM2 (Dynamin 2), RNH1 (Ribonuclease/angiogenin Inhibitor 1), AP2M1 (Adaptor Related Protein Complex 2 Subunit Mu 1), HLA-A (Major Histocompatibility Complex, Class I, A), TPI1 (Triosephosphate Isomerase 1), TUBB4B (Tubulin Beta 4B Class IVb), ACTR1A (ARP1 Actin-Related Protein 1 Homolog A, Centractin Alpha), RPL23A (Ribosomal Protein L23a), LAMP2 (Lysosomal Associated Membrane Protein 2), ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide), SCL25A11 (Solute Carrier Family 25 Member 11), UBE2V1 (Ubiquitin Conjugating Enzyme E2 V1), NDUFS7 (NADH:Ubiquinone Oxidoreductase Core Subunit S7), PSAT1 (Phosphoserine Aminotransferase 1), SAA1 (Serum Amyloid A1), CD248 (Endosialin), ANXA5 (Annexin A5), UGGT1 (UDP-Glucose Glycoprotein Glucosyltransferase 1), EIF4G1 (Eukaryotic Translation Initiation Factor 4 Gamma 1).